Literature DB >> 18349518

Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.

Kurt A Jellinger1.   

Abstract

BACKGROUND: The clinical and pathological heterogeneity of progressive supranuclear palsy (PSP) is well established. Recent clinicopathological studies showed much more severe and more widespread tau pathology in Richardson's syndrome (RS), clinically manifest by early onset, falls, supranuclear gaze palsy, dementia and shorter disease duration than in atypical PSP-parkinsonism (PSP-P) often mimicking Parkinson's disease, in which tau pathology is relatively restricted to substantia nigra, subthalamic nucleus and internal globus pallidus.
OBJECTIVE: To perform a comparative clinicopathological study of 30 autopsy-proven cases of PSP.
METHODS: Retrospective assessment of major clinical signs in 18 patients referred to as RS and 12 PSP-P, and semiquantitative assessment of the severity and distribution pattern of tau pathology in both phenotypes using routine stains and immunohistochemistry.
RESULTS: RS (61% males) and PSP-P (33% males) showed significant differences in clinical symptomatology and course (RS mean duration 4.2 years, PSP-P 13.8 years) and significant differences in histopathology: widespread tau pathology and related multisystem degeneration in RS and more restricted lesions in PSP-P, which, however, were not only involving predominantly the subthalamo-nigral-pallidal system. Cortical tau pathology in both groups was usually restricted to limbic areas, and neocortical Alzheimer-type pathology was only seen in very old or demented PSP patients.
CONCLUSIONS: The present study confirmed the recently reported existence of two distinct clinical phenotypes in patients with pathologically proven PSP-P and RS, showing significant differences in severity and distribution of tau pathology, the latter more severe and more widely distributed than in PSP-P. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349518     DOI: 10.1159/000121388

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  15 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

Review 2.  Co-existence of Parkinson's disease and progressive supranuclear palsy: case report and a review of the literature.

Authors:  Kumar Abhinav; Laura Marsh; Barbara Crain; Stephen G Reich; Kevin Biglan
Journal:  Neurol Sci       Date:  2010-08-25       Impact factor: 3.307

3.  The relationship between clinical and pathological variables in Richardson's syndrome.

Authors:  Emma C Schofield; John R Hodges; Thomas H Bak; John H Xuereb; Glenda M Halliday
Journal:  J Neurol       Date:  2011-08-12       Impact factor: 4.849

4.  Instability of syllable repetition in progressive supranuclear palsy.

Authors:  Sabine Skodda; Wenke Grönheit; Uwe Schlegel
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

5.  In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism.

Authors:  Karin Srulijes; Grit Mallien; Sarah Bauer; Elisabeth Dietzel; Adriane Gröger; Georg Ebersbach; Daniela Berg; Walter Maetzler
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

6.  Multimodal MRI evaluation of parkinsonian limbic pathologies.

Authors:  Ernest W Wang; Guangwei Du; Mechelle M Lewis; Eun-Young Lee; Sol De Jesus; Sangam Kanekar; Lan Kong; Xuemei Huang
Journal:  Neurobiol Aging       Date:  2019-01-16       Impact factor: 4.673

Review 7.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

8.  Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study.

Authors:  Salvatore Nigro; Angelo Antonini; David E Vaillancourt; Klaus Seppi; Roberto Ceravolo; Antonio P Strafella; Antonio Augimeri; Andrea Quattrone; Maurizio Morelli; Luca Weis; Eleonora Fiorenzato; Roberta Biundo; Roxana G Burciu; Florian Krismer; Nikolaus R McFarland; Christoph Mueller; Elke R Gizewski; Mirco Cosottini; Eleonora Del Prete; Sonia Mazzucchi; Aldo Quattrone
Journal:  Mov Disord       Date:  2020-02-24       Impact factor: 10.338

9.  Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study.

Authors:  Milica Jecmenica-Lukic; Igor N Petrovic; Tatjana Pekmezovic; Vladimir S Kostic
Journal:  J Neurol       Date:  2014-06-03       Impact factor: 4.849

10.  Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?

Authors:  Ali Shoeibi; Irene Litvan; Jorge L Juncos; Yvette Bordelon; David Riley; David Standaert; Stephen G Reich; David Shprecher; Deborah Hall; Connie Marras; Benzi Kluger; Nahid Olfati; Joseph Jankovic
Journal:  Parkinsonism Relat Disord       Date:  2019-10-14       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.